-
A recent retrospective study utilizing data from the China National Mortality Surveillance System has shed light on the mortality rates associated with pulmonary heart disease (PHD) in China. The study found that the age-standardized mortality rate of PHD has significantly decreased from 61.68 per 100,000 in 2014 to 28.53 per 100,000 in 2021. The analysis also revealed that PHD-related deaths primarily occur in older individuals, with those aged over 80 being the most affected. Chronic obstructive pulmonary disease (COPD) was identified as the main underlying cause of death in the majority of PHD cases. Despite the declining trend in mortality rates, the study emphasized the need for continued attention to PHD due to the high prevalence of COPD and the rapid population aging in China. This study provides valuable insights into the current status and trends of PHD-associated mortality, helping healthcare professionals and policymakers understand the impact of PHD on public health in China.
PHD, also referred to as cor pulmonale, is characterized by pulmonary arterial hypertension stemming from conditions, including chronic respiratory disease, chronic thromboembolic pulmonary hypertension, and other diseases impacting the lung’s structure or function. This condition can result in right ventricular enlargement, potentially leading over time to right heart failure (1). PHD was a significant heart disease in China during the latter half of the previous century. From the 1990s, advancements in technology and methodologies have enhanced the treatment and survival rate of this condition. According to the third national retrospective survey on causes of death, the PHD mortality rate was 4.74 per 100,000 (2). However, this mortality rate was based on the underlying cause of death (UCoD) and did not accurately reflect the actual number of PHD related deaths, as many such instances were classified with chronic obstructive pulmonary disease (COPD) as the UCoD. The proportion of PHD deaths attributed to COPD in the Chinese population remains uncertain. Thus, this analysis was conducted using data from the China National Mortality Surveillance System (NMSS) to provide a comprehensive update on PHD related mortality in recent years in China and to investigate the fundamental causes of PHD-related deaths.
-
In 2021, the total number of PHD associated death was 103,586 (61,634 males, and 41,952 females) across 605 DSPs, leading to an estimated 430,205 PHD deaths nationwide. The ASMR showed a decrease, falling from 61.68 per 100,000 in 2014 to 28.53 per 100,000 in 2021 (AAPC= −10.40 , 95% confidence interval (CI): −12.03 to −8.75), with a reduction of 53.74% (Table 1).
Category 2014 2021 AAPC for ASMR Number AMR ASMR Number AMR ASMR Total 156,418 47.93 61.68 103,586 30.46 28.53 −10.40* (−12.03, −8.75) Gender Male 87,784 52.54 76.14 61,634 35.51 38.14 −9.31* (−11.15, −7.44) Female 68,634 43.10 49.26 41,952 25.20 20.38 −11.80* (−13.24, −10.33) Urban-Rural Urban 39,456 30.39 41.10 25,720 16.94 16.68 −12.26* (−13.82, −10.67) Rural 116,962 59.53 73.93 77,866 41.36 37.08 −9.17* (−10.95, −7.73) Region East 53,685 37.47 44.69 28,223 17.88 16.28 −13.46* (−14.79, −12.11) Central 44,398 45.07 60.42 29,230 30.35 27.50 −10.46* (−13.38, −7.43) West 58,335 69.00 96.62 46,133 53.69 53.84 −7.95* (−11.09, −4.70) Abbreviation: AAPC=average annual percent change; AMR=adjusted mortality rate; ASMR=age-standardized mortality rate; PHD=pulmonary heart disease; DSPs=disease surveillance points.
* P<0.01.Table 1. Number of deaths, ASMR and AMR (per 100,000) of PHD by gender, urban-rural divide, and region in 605 DSPs in 2014 and 2021.
The ASMR exhibited a significant decline in males from 76.14 per 100,000 in 2014 to 38.14 per 100,000 in 2021 (AAPC=−9.31, 95% CI: −11.15 to −7.44). Similarly, in females, ASMR decreased from 49.26 per 100,000 in 2014 to 20.38 per 100,000 in 2021 (AAPC=−11.80, 95% CI: −13.24 to −10.33). The ASMR was reduced by 49.91% in males and 58.63% in females (Table 1).
Significant variations in the ASMR were reported across different regions. Over the study period, the highest ASMR was observed in the west region, higher than that in the central and east regions (Table 1). From 2014 to 2021, there was a decrease in ASMR from 44.69 to 16.28 per 100,000 in the east region (AAPC=−13.46, 95% CI: −14.79 to −12.11). In the central region, it decreased from 60.42 to 27.50 per 100,000 (AAPC=−10.46, 95% CI: −13.38 to −7.43). The west region reported a decrease in ASMR from 96.62 to 53.84 per 100,000 (AAPC=−7.95, 95% CI: −11.09 to −4.70). The decrease of the ASMR corresponded to 63.57%, 54.49%, and 44.28%, respectively.
The ASMR exhibited a significant decrease in both urban and rural areas during the study period. Specifically, the ASMR in urban areas dropped from 41.10 per 100,000 to 16.68 per 100,000 (AAPC=−12.26, 95% CI: −13.82 to −10.67), representing a 59.42% decrease. Meanwhile, in rural areas, the ASMR descended from 73.93 per 100,000 to 37.08 per 100,000 (AAPC=−9.17, 95% CI: −10.95 to −7.37), reflecting a 49.84% reduction (Table 1).
Mortality rates associated with PHD escalated with age, demonstrating a sharp increase after 60–65 age group across all categories (Figure 1). The highest mortality rate was observed in individuals aged over 80. Throughout the study period, a decreasing trend was evident in the mortality rates across all age groups.
Figure 1.Trends in age-specific mortality rates for pulmonary heart disease in China in 2014, 2016, 2018, and 2021. Among age groups based on (A) all population, (B–C) sex (male and female), (D–E) residential area (urban or rural), and (F–H) region (East, Central or West China).
Table 2 presents a summary of the underlying causes of PHD-associated deaths from 2014 to 2021. Notably, COPD is identified as the leading underlying cause of these PHD-associated deaths, comprising the majority of total cases.
Underlying cause of death 2014, n (%) 2015, n (%) 2016, n (%) 2017, n (%) 2018, n (%) 2019, n (%) 2020, n (%) 2021, n (%) N*=156,418 N=142,733 N=144,424 N=140,379 N=133,047 N=126,552 N=108,196 N=103,586 Chronic obstructive pulmonary disease 136,725
(87.41)131,343
(92.02)134,324
(93.01)130,864
(93.22)123,830
(93.07)117,280
(92.67)99,918
(92.35)93,928
(90.68)Pulmonary heart disease 14,161
(9.05)5,918
(4.15)4,221
(2.92)3,767
(2.68)3,651
(2.74)3,638
(2.87)3,423
(3.16)5,051
(4.88)Other primary disease of pulmonary heart disease 1,353
(0.86)1,543
(1.08)1,782
(1.23)1,867
(1.33)1,830
(1.38)2,004
(1.58)1,643
(1.52)1,564
(1.51)Ischemic heart disease 937
(0.60)802
(0.56)845
(0.59)770
(0.55)851
(0.64)727
(0.57)647
(0.60)702
(0.68)Tumors 605
(0.39)593
(0.42)612
(0.42)604
(0.43)592
(0.44)530
(0.42)519
(0.48)441
(0.43)Cerebrovascular disease 245
(0.16)198
(0.14)227
(0.16)236
(0.17)239
(0.18)286
(0.23)236
(0.22)241
(0.23)Other disease 2,392
(1.53)2,336
(1.64)2,413
(1.67)2,271
(1.62)2,054
(1.54)2,087
(1.65)1,810
(1.67)1659
(1.60)Abbreviation: PHD=pulmonary heart disease; DSPs=disease surveillance points.
* Total number of PHD-associated deaths.Table 2. Underlying causes of PHD-associated deaths among 605 DSPs in China from 2014 to 2021.
HTML
Citation: |